Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04321070 · ClinicalTrials.gov registry record · Phase 1
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
A Phase 1 study, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 1
- Development phase
- 550
- Enrollment target
NCT04321070 is a Phase 1 study that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 550 participants.
The verdict
NCT04321070, a Phase 1 study, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 550 participants
- Enrollment target
Study Summary
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
Interventions
- DRUG Placebos
- DRUG Clindamycin Phosphate
- DRUG Clindamycin Phosphate RLD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 550 participants |
| Start Date | 2019-09-09 |
| Est. Completion | 2020-03-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04321070
The ClinicalTrials.gov registry entry for NCT04321070 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 550 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebos is the first listed.
NCT04321070 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04321070 about?
NCT04321070 is a clinical study titled "Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris". Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
What is the current status of trial NCT04321070?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 550 participants. The study started on 2019-09-09. Estimated completion is 2020-03-06.
What interventions are being tested in trial NCT04321070?
The interventions under investigation include: Placebos (DRUG), Clindamycin Phosphate (DRUG), Clindamycin Phosphate RLD (DRUG).
Who is sponsoring clinical trial NCT04321070?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.